KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenueProperty, Plant & Equipment, Net BreakdownR&D As A %R&D SegregationRevenueRevenue By Customer TypeRevenue By Customer Type %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue By SegmentRevenue By Segment %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2025)

Acadia Pharmaceuticals has reported Gross Profit over the past 10 years, most recently at $257.8 million for Q4 2025.

  • Quarterly results put Gross Profit at $257.8 million for Q4 2025, up 8.4% from a year ago — trailing twelve months through Dec 2025 was $982.5 million (up 12.16% YoY), and the annual figure for FY2025 was $982.5 million, up 12.16%.
  • Gross Profit for Q4 2025 was $257.8 million at Acadia Pharmaceuticals, roughly flat from $257.0 million in the prior quarter.
  • Over the last five years, Gross Profit for ACAD hit a ceiling of $257.8 million in Q4 2025 and a floor of $104.4 million in Q1 2021.
  • Median Gross Profit over the past 5 years was $170.3 million (2023), compared with a mean of $175.8 million.
  • Biggest five-year swings in Gross Profit: grew 0.51% in 2022 and later soared 58.98% in 2023.
  • Acadia Pharmaceuticals' Gross Profit stood at $120.0 million in 2021, then grew by 11.72% to $134.1 million in 2022, then surged by 58.98% to $213.2 million in 2023, then increased by 11.56% to $237.8 million in 2024, then increased by 8.4% to $257.8 million in 2025.
  • The last three reported values for Gross Profit were $257.8 million (Q4 2025), $257.0 million (Q3 2025), and $243.8 million (Q2 2025) per Business Quant data.